%PDF-1.4
%
89 0 obj
<>
endobj
86 0 obj
<>
endobj
147 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T08:59:33Z
2024-03-28T17:06:40-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T17:06:40-07:00
application/pdf
Heather
2003-864.april suppl 70
uuid:048249ed-1dd2-11b2-0a00-5f08275dc400
uuid:048249f0-1dd2-11b2-0a00-810000000000
endstream
endobj
75 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 63 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
165 0 obj
[169 0 R]
endobj
166 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1926 Tw 10 0 0 10 54 713.1622 Tm
[(Further)39.7 (, there was not much dif)17.7 (ference between )54.8 (African-)]TJ
0.0985 Tw 0 -1.2 TD
(American and Caucasian men with respect to mean serum)Tj
0.15311 Tw T*
[(COMP)-366.3 (levels. However)39.7 (, regardless of status of their OA,)]TJ
0.01109 Tw T*
(African-American women had significantly higher levels of)Tj
0.02499 Tw T*
[(COMP)-238.3 (than Caucasian women)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 177.9629 668.4622 Tm
(10)Tj
10 0 0 10 184.4629 665.1622 Tm
(.)Tj
-0.00011 Tc 0.16789 Tw -11.8463 -1.2 Td
[(W)79.9 (e confirmed that COMP)-381.2 (levels were associated with)]TJ
0.0771 Tw -1.2 -1.2 Td
[(age, as noted previously)64.8 (. )17.7 (The ethnic and sex dif)17.7 (ferences in)]TJ
0.1239 Tw T*
[(serum COMP)-337.2 (could not be explained, however)39.7 (, by dif)17.7 (fer-)]TJ
0.05389 Tw T*
(ences in age, BMI, height, the presence or severity of radi-)Tj
0.02499 Tw T*
(ographic OA, or the presence of other symptomatic joints.)Tj
0.0199 Tc 0.3558 Tw 1.2 -1.2 Td
[(In developing standards for serum COMP)-588.9 (and in)]TJ
-0.00011 Tc 0.09039 Tw -1.2 -1.2 Td
(collecting normative data, it will be important to take age,)Tj
0.0009 Tw T*
(sex, and ethnicity into account. In addition, postmenopausal)Tj
0.2704 Tw T*
(women who receive hormone replacement therapy have)Tj
-0.0365 Tw T*
[(lower COMP)-176.7 (levels than women who do not)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 229.6453 548.4622 Tm
(12)Tj
-0.00011 Tc -0.03661 Tw 10 0 0 10 236.1452 545.1622 Tm
(. Despite these)Tj
0.1514 Tw -18.2145 -1.2 Td
[(variables, COMP)-364.7 (may be an important biomarker of OA.)]TJ
0.15199 Tw T*
(Although it is unlikely to be useful as a solitary test, the)Tj
0.10921 Tw T*
[(possibility that COMP)-322.4 (may be useful in combination with)]TJ
0.16789 Tw T*
(other biomarkers or other demographic data is worthy of)Tj
0.02499 Tw T*
[(further study)64.8 (.)]TJ
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.2635 Tw 8 0 0 8 54 451.1622 Tm
[(I acknowledge the close collaboration of Dr)54.8 (. )17.7 (V)59.8 (i)0.3 (r)17.7 (ginia Kraus of Duke)]TJ
0.0587 Tw 0 -1.25 TD
[(University Medical Center)39.7 (, whose laboratory performed all the biomarker)]TJ
0.02499 Tw T*
(measurements discussed.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 54 407.1622 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 397.1622 Tm
[(1.)-875.1 (Neidhart M, Hauser N, Paulsson M, DiCesare PE, Michel BA,)]TJ
1.675 -1.25 Td
(Hauselmann HJ. Small fragments of cartilage oligomeric matrix)Tj
T*
(protein in synovial fluid and serum as markers for cartilage )Tj
T*
[(degradation. Br J Rheumatol 1997;36:1)36.8 (151-60.)]TJ
-1.675 -1.25 Td
[(2.)-875.1 (Sharif M, Saxne )17.7 (T)74 (, Shepstone L, et al. Relationship between serum)]TJ
1.675 -1.25 Td
(cartilage oligomeric matrix protein levels and disease progression)Tj
T*
(in osteoarthritis of the knee joint. Br J Rheumatol 1995;34:306-10.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Petersson IF)79.7 (, Boegard )17.7 (T)74 (, Svensson B, Heinegard D, Saxne )17.7 (T)74 (.)]TJ
1.675 -1.25 Td
(Changes in cartilage and bone metabolism identified by serum)Tj
33 49.671 Td
(markers in early osteoarthritis of the knee joint. Br J Rheumatol)Tj
0 Tc 0 Tw T*
(1998;347:46-50.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Conrozier )17.7 (T)74 (, Saxne )17.7 (T)74 (, Fan CS, et al. Serum concentrations of )]TJ
1.675 -1.25 Td
(cartilage oligomeric matrix protein and bone sialoprotein in hip)Tj
T*
[(osteoarthritis: a one year prospective study)64.8 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1998;57:527-32.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Murphy E, FitzGerald O, Saxne )17.7 (T)74 (, Bresnihan B. Increased serum)]TJ
1.675 -1.25 Td
(cartilage oligomeric matrix protein levels and decreased patellar)Tj
T*
[(bone mineral density in patients with chondromalacia patellae. )54.8 (Ann)]TJ
T*
(Rheum Dis 2002;61:981-5.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (V)59.8 (ilim )17.7 (V)128.9 (,)-0.1 ( )17.7 (V)128.9 (oburka Z, )17.7 (V)110.8 (ytasek R, et al. Monoclonal antibodies to)]TJ
1.675 -1.25 Td
(human cartilage oligomeric matrix protein: epitope mapping and)Tj
T*
[(characterization of sandwich ELISA. Clin Chim )54.8 (Acta )]TJ
0 Tc 0 Tw T*
(2003;328:59-69.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Clark )54.8 (AG, Jordan JM, )17.7 (V)59.8 (ilim )17.7 (V)128.9 (, et al. Serum cartilage oligomeric)]TJ
1.675 -1.25 Td
(matrix protein reflects osteoarthritis presence and severity: the)Tj
T*
[(Johnston County Osteoarthritis Project. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1999;42:2356-64.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (V)59.8 (ilim )17.7 (V)128.9 (,)-0.1 ( )17.7 (V)110.8 (ytasek R, Olejarova M, et al. Serum cartilage oligomeric)]TJ
1.675 -1.25 Td
(matrix protein reflects the presence of clinically diagnosed)Tj
T*
(synovitis in patients with knee osteoarthritis. Osteoarthritis)Tj
T*
(Cartilage 2001;9:612-8.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (V)59.8 (ilim )17.7 (V)128.9 (, Olegarova M, Machacek S, Gatterova J, Kraus )17.7 (VB,)]TJ
1.675 -1.25 Td
(Pavelka K. Serum levels of cartilage oligomeric matrix protein)Tj
T*
(\(COMP\) correlate with radiographic progression of knee)Tj
T*
(osteoarthritis. Osteoarthritis Cartilage 2002;10:707-13.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Jordan JM, Luta G, Stable )17.7 (T)74 (, et al. Ethnic and gender dif)17.7 (ferences in)]TJ
2.175 -1.25 Td
[(serum cartilage oligomeric matrix protein: )17.7 (The Johnston County)]TJ
T*
[(Osteoarthritis Project. )54.8 (Arthritis Rheum 2003;48:675-81.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Dragomir )54.8 (AD, Kraus )17.7 (VB Renner JB, et al. Serum cartilage)]TJ
2.1381 -1.25 Td
(oligomeric matrix protein increases with signs and symptoms of)Tj
T*
(knee and hip arthritis in the absence of radiographic knee and hip)Tj
T*
(osteoarthritis: the Johnston County Osteoarthritis Project.)Tj
T*
(Osteoarthritis Cartilage 2002;10:687-91.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Dragomir )54.8 (AD, )54.8 (Arab L, Luta G, et al. Current hormone replacement)]TJ
2.175 -1.25 Td
[(therapy \(HR)59.7 (T\) and symptomatic knee and hip osteoarthritis \(OA\) in)]TJ
T*
[(postmenopausal )54.8 (African-American and Caucasian women)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 2002;46 Suppl:S469.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Jor)36.8 (dan: COMP)-257.3 (as OA)-257.3 (marker)]TJ
0 Tc 0 Tw 61.9375 -0.0313 Td
(49)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>stream
8;Z\7$a.B$#ikn#j>taoK7Oa->G%caGhT/E.C"F:``sqi'I^kG7M`\PIm\Sm??;Kp
D6^k0--n8`^Tmr2Hh0iU'FKhq=&Bsi)W:]_rSU*H2be5_n;PIMa+6MK\oP?/*dN2H
cM(iYVR5b22n'4'a[K;hV2Pg-NnlqWNbKpBR6#aqVHMTp]=DF0NQ,2fo5Q1F&-\2i
V/;9S=cf*kLg4rs%WO2!@t.d\NA7DNM#M,gNeM;2@6"kpN)L=NF\1m
jl,E7'Zj7bg8P\8Y;guD^)n4j>D:\(!AP>.?G+G*s,8XJ6oF'XENpd=I6JHdERuO8QtYn&QTE
920def&!f`[LX"k;ntU9Qh&a;ek8A2DA[V&bZ[N_ER;CCue$EVA(CUAEEJPa)U7
79LaD7N)ZdC3D+iLpkn5>B,6egl7W""7Fr=9q&CH7tZ`O[SE
endstream
endobj
73 0 obj
[/Indexed/DeviceRGB 255 72 0 R]
endobj
72 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
136 0 obj
<>
endobj
92 0 obj
<>
endobj
54 0 obj
<>
endobj
95 0 obj
<>
endobj
125 0 obj
<>
endobj
152 0 obj
<>
endobj
93 0 obj
<>
endobj
117 0 obj
<>stream
HlUyPSy~/Q\Bc1"Z((2!\B8BBK:*x+8,U2?v?SU_uu_Wu7Y0l
ۺ}Xǥ62_.),7HOܴ|Q@Idz7"š44L6[!BCd0L0;[)6]xf#fw:*5e䔉5ܨ]ofg`5->`1Y`]3딩"U'*ȽI_ICoSѭ>VTO`|䱁bI1Ll6܅W$G6̌0q`<i@kD&E-tY2Idv%tm6_֣U"B4ZTzGgesJ)Ƈ`&LPGYs=&4 TӠNRX(]N6mD64q>O֧4vϓw'aNjk ő˹JE:QAvu{*,9y8*INiٽݾ7F#Ӽ>cn~鞠#);a|q5ěK֞Mg{4I9A¨h=-2Jn
ծ=W'.ZDZ&:Ϙz$ĵ8=0F|tu-xܾ1
?"%P_M4ڿm}Mgr;
y@Q]kB.}|¨E)jF|-yrBPQhf1=Hbsl/a;"C/9Sk$=tIRL!D9qK|)GNoyQv*6LT*X k m5^7˛9V#STif7uG:t-gʡUTȃB 2U^ $ʢ;{uKgn1*DBRΩ-l,զwSX0q㌝`~տ02^$H,)Xo%li| $d[r&p%WN=zVṄyK!/,ғ(~,OP4Cy-VD